Overview

Lapatinib in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well lapatinib works in treating patients with prostate cancer that did not respond to hormone therapy.
Phase:
Phase 2
Details
Lead Sponsor:
UNC Lineberger Comprehensive Cancer Center
Collaborators:
GlaxoSmithKline
National Cancer Institute (NCI)
Treatments:
Hormones
Lapatinib